Study: Pembrolizumab versus ipilimumab for advanced melanoma
31 Aug, 2017 | 20:31h | UTCPembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006) – The Lancet (link to abstract – $ for full-text)
Commentary: Pembrolizumab Prolongs Overall Survival Compared With Ipilimumab in Melanoma – Cancer Therapy Advisor (free)
Source: Richard Lehman’s journal review (free)